



Astal Laboratories Limited

ASTAL LABORATORIES LIMITED

(Formerly known as MACRO INTERNATIONAL LIMITED)

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301

Corporate Office: 8-2-351/w/3/4, Road Number 3, Banjara Hills, Hyderabad, Telangana, 500034

SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India

Email: meil100@rediffmail.com; Mob. No: 6302730973, Website: <https://astallabs.com/>

Date: 31/01/2025

To,
The Deputy Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001

Subject: Press Release Under Regulation 30 SEBI (Listing Obligation and Disclosure Requirements)
Regulation, 2015

Ref.: Scrip Code: 512600

Security Id: ASTALLTD

Respected Sir/Madam,

Please find attached herewith a copy of the Proposed Press Release to be issued by the Company.

The same is also being uploaded on website of the Company at <https://astallabs.com/>

You are requested to take the above on record.

Thanking You,

Yours Faithfully,

For Astal Laboratories Limited

Mahendra Kumar
(Company Secretary & Compliance Officer)
Membership No.: A71224

Press Release: Astal Laboratories Limited: A prominent player in the Active Pharmaceutical Ingredients (API) and bulk drug manufacturing sector; delivering Robust Quarter 3, FY 2024-25 performance & future outlook.

Key Highlights of Q3 FY 2024-25 Financial Results (Standalone):

- **Revenue from Operations** for Q3 FY 2024-25 increased to **INR 1,445.88 Lakhs**, a **71.9% YoY growth** compared to INR 841.23 Lakhs in the corresponding quarter of the previous year.
- **Total Revenue** for the quarter stood at **INR 1,451.47 Lakhs**, a **72.5% YoY increase**.
- **Profit Before Tax (PBT)** rose to **INR 301.79 Lakhs**, a **519% YoY growth** from INR 48.73 Lakhs in Q3 FY 2023-24.
- **Profit After Tax (PAT)** for the quarter reached **INR 248.86 Lakhs**, a **410% YoY increase**.
- **Earnings Per Share (EPS)** for the quarter stood at **INR 2.528**, a **149% YoY growth** compared to INR 1.015 in the same period last year.
- **9-Month Revenue** for FY 2024-25 reached **INR 4,085.44 Lakhs**, a **258% YoY increase** from INR 1,140.76 Lakhs in the previous year.
- **9-Month PAT** grew to **INR 618.05 Lakhs**, a **1,072% YoY increase**.

January 31, 2025 Hyderabad, India — Astal Laboratories Limited (formerly known as Macro International Limited) (BSE: 512600), a prominent player in the Active Pharmaceutical Ingredients (API) and bulk drug manufacturing sector, has announced its unaudited financial results for the quarter and nine months ended December 31, 2024. The results reflect significant growth in revenue and profitability, underscoring the company's steady progress in the pharmaceutical industry.

Growth Strategy:

Astal Laboratories has been focusing on **strategic expansions, operational efficiencies, and innovative product offerings**. The company's emphasis on **high-margin APIs and bulk drugs** has strengthened its position in both domestic and international markets. With a **robust pipeline** of new products and a **growing global presence**, Astal is well-positioned for **continued growth** in the pharmaceutical sector.

Management Commentary:

Mr. Sudheer Karna Kankanala, Whole Time Director of Astal Laboratories, commented,

*“The Q3 results reflect our commitment to growth and operational excellence. We have achieved **strong financial performance** this quarter, driven by our focus on innovation, efficiency, and market expansion. As we move forward, we remain dedicated to delivering value to our stakeholders and strengthening our position in the API and bulk drug manufacturing space.”*

Future Outlook:

Astal Laboratories is focused on achieving **sustained growth** in the coming years. The company plans to:

- **Expand its product portfolio** with high-value APIs and specialty chemicals.
- **Enhance manufacturing capabilities** through strategic investments in modern facilities.
- **Increase its presence** in international markets, including Europe, Japan, and the USA.
- **Leverage R&D** to develop innovative solutions that meet the evolving needs of the pharmaceutical industry.

Investor Confidence:

Astal Laboratories' **consistent performance** has reinforced **investor confidence**, with the company's stock showing **positive momentum** in recent months. The management remains committed to delivering **long-term value** to its shareholders through **sustainable growth** and **strategic initiatives**.

About Astal Laboratories Limited:

Astal Laboratories Limited (formerly Macro International Limited) is a **leading manufacturer** and trader of Active Pharmaceutical Ingredients (APIs) and bulk drugs. Headquartered in Hyderabad, India, the company is known for its **advanced technology**, **high-quality products**, and **customer-centric approach**. With a **strong presence** in both domestic and international markets, Astal is contributing to the growth of the pharmaceutical industry.

For further information, please contact:

Mr. Balayogiswara Rao Peddinti – Chief Financial Officer
Meil100@refiffmail.com

Website: <https://astallabs.com>